Vulvo-vaginal lichen planus is a condition which imposes a significant burden of symptoms and sequale. There is a paucity of knowledge and evidenced-based management with significant diagnostic delay prior to appropriate treatment being common. There remains great variability in clinician practice in the context of limited knowledge. This clinical review presents current evidence on the clinicopathological features, practical assessment and management options. Learning points include characterization of this chronic, burdensome clinical entity that has no standardized diagnostic or management protocols. We provide practical clinical conclusions based on current knowledge and identify areas for future research to improve patient outcomes.
INTRODUCTION
Vulvo-vaginal lichen planus (VLP) is a debilitating chronic inflammatory condition that has a significant impact on patients' quality of life. 1 It may involve solely the genital skin and mucosa but the oral, oesophageal and anal mucosa may also be affected. 2 Diagnosis and management are hampered by lack of evidence-based diagnostic criteria, large cohort studies or clinical trials. Symptoms and signs of disease and severity are highly variable and range from a non-specific erythematous vulvo-vaginitis to severe scarring, erosions and vaginal obliteration. 3 The variability in clinical presentation, lack of other cutaneous signs, unreliability and inconsistent use of histopathology may result in significant diagnostic difficulty. 4 Management often requires a multidisciplinary approach with involvement of dermatologists, gynaecologists and physiotherapists. There is no known cure and focus of therapy is to control symptoms and improve quality of life with treatment that has an acceptable side effect profile. Clinical follow-up, over years, is vital due to the chronic nature of the disease, the possibility of relapse and the development of sequale whose range remains unclear. 5 
METHOD
The PubMed, EMbase, The Cochrane Library, MedLine and Clinical Practice Guideline Network (CPGN) were systematically searched through April 2018 for articles relating to VLP. The Mesh search terms were: 'mucosal lichen planus', 'vulval lichen planus', 'vulvar lichen planus', 'vaginal lichen planus', 'lichen planus' 'erosive lichen planus' 'vulval dermatoses', 'lichen planus diagnosis', 'lichen planus treatment' and 'lichen planus outcomes' 'lichen planus quality of life'. A total of 58 articles concerning lichen planus of the vulvo-vaginal unit were found from 1964 to 2017. Papers published in a language other than English were excluded with the remaining 47 included in the review.
RESULTS
Vulvo-vaginal lichen planus is more common in older, postmenopausal women, usually diagnosed in those between the ages of 50 and 60. 6 The definitive incidence of VLP is unknown, but a prevalence of 1% to 2% in the general population has been suggested. 5 In a study of 3350 women in a vulvar dermatology clinic, 3.7% had biopsy-proven VLP. 6 VLP is important to consider in any patient with oral or cutaneous disease, regardless of vulvar symptoms, as studies note that VLP was found in 57% of patients with oral lichen planus (LP) whilst 51% of 37 women with cutaneous lichen planus had vulvar disease. [7] [8] [9] Although unconfirmed, VLP is most likely a T-cellmediated inflammatory disease with a hitherto unidentified self or exogenous antigen inducing a CD8+ T lymphocyte response resulting in the basal keratinocytes degeneration seen in dermal inflammatory infiltrate. 1 Similarly to lichen sclerosus, an autoimmune origin for VLP is made likely by a link with other autoimmune diseases, family history of other autoimmune conditions and circulating organ-specific antibodies. 10 There is an association of lichen planus with other autoimmune diseases including alopecia areata, vitiligo and thyroid disease. 10 A significant study reported that antibasement membrane zone antibodies that target BP180 are present in 61% of patients' serum samples in confirmed VLP.
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Diagnosis
The varied and non-specific nature of the clinical features associated with VLP have made the diagnostic process a topic of discussion in the literature. 12, 13 Findings of most reported cohorts are that pain, pruritus, dyspareunia, discharge and irritation were the most common presenting complaints whilst the most frequent vulval signs are erosions, red and/or purple coloration and scarring. 2, 14, 15 Three main clinicopathological forms of VLP are recognized as the classic, hypertrophic and erosive types. 16 The most treatment responsive of these, the classic type, is rare and frequently asymptomatic. 2 It is notably associated with cutaneous LP with its typical Wickham striae, white reticulate and lacy lesions, over the labia minora and clitoral hood. 16 ( Fig. 1) Clusters of papules are often demonstrated over the interlabial sulci and labia majora. 2 This classical form frequently resolves spontaneously and without causing scarring or architectural loss.
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Whilst many authors propose that hypertrophic LP very rarely affects genital skin, it may involve the perineum and perianal area. 1 Most active disease is frequently seen as pruritic plaques associated with a purplish or violaceous edge. 2 Whilst some authors are confident that this type is uniquely vaginal sparring, it can mimic malignancy and biopsy is essential. 1, 13, 16 Erosive vulvo-vaginal lichen planus (erosive VLP) is the most common variant. 4 Symptoms include pain, dyspareunia and blood-stained vaginal discharge in up to 70% of patients. 17 The fourchette and anterior vestibule are involved symmetrically with erosions that often carry a white, 'lacy' edge. 16 Chronic inflammation leads to scarring of the labia minora, vulval trigone and vaginal vault leading to loss of normal architecture with clitoral burying and narrowing of the introitus (Fig. 2) . 2 Patients with dysphagia or odynophagia should be examined closely as oesophageal involvement in erosive VLP is increasingly being reported in the literature along with occasional oesophageal malignancies. 18 The vulvo-vaginal-gingival syndrome is a severe subtype of erosive VLP. [19] [20] [21] It involves erythematous, friable vaginal lesions that potentially develop into synechiae and complete vaginal stenosis with resultant haematocolpos in severe cases. 21, 22 These sequalae often result from delayed diagnosis. 19 Diagnostic criteria for erosive VLP have been proposed, including a consensus amongst 73 clinicians with an eDelphi exercise conducted to produce a diagnostic algorithm. 3, 4 It consists of nine features, three of which must be present to support a diagnosis of erosive VLP. 4 It is important to note that these criteria are not evidence based, specific in context of vulvo-vaginal dermatoses and have not been externally validated to date. When the diagnosis of VLP is suspected clinically, it is prudent to obtain histopathology with the biopsy taken from the edge of the erosion.
14 However, previous studies have shown that only 71% of specimens return a definite diagnosis. 23 A diagnostic biopsy in VLP carries a pathognomonic inflammatory reaction pattern. The epidermis is hyperkeratotic with hypergranulosis, acanthosis, saw tooth rete ridges and dyskeratosis with an intense bandlike inflammatory infiltrate is seen in the dermis or submucosa. 2, 12, 16 Liquefactive degeneration of the basal layer and destruction of the basement membrane occur. 24 Civatte bodies are commonly noted in the lower epithelium or the submucosa. 25 In VLP, direct immunofluorescence reveals shaggy deposition of IgG, IgM, IgA, C3 and fibrin at the basement membrane. 18 This classic confirmatory picture is, however, not present in all cases.
13 Figure 1 Mild VLP with slight hyperkeratotic border to peri-9 clitoral lesions, patient also complained of non-infective discharge. Low vaginal swabs taken from patients with VLP commonly demonstrate sheets of lymphocytes or polymorphonuclear leucocytes, decrease in numbers of normal keratinocytes and an increase in immature squamous cells. 12 These are also found in other erosive or inflammatory disease that affects the vagina. 1 Therefore, in practice, swabs can only be used to exclude an infective process.
Ultimately, a diagnosis of VLP often becomes one of exclusion in the absence of diagnostic histopathology and is a decision made on clinical characteristics and suggestive histopathologic features in the absence of reliable diagnostic protocols.
Management
The literature regarding therapy for VLP is mostly limited to anecdotal observations or small case series with no large randomized controlled trials.
When VLP is in the differential diagnosis, a medication review should be conducted for each patient and if any drugs associated with lichenoid or fixed drug eruptions that can mimic VLP (e.g. beta-blockers, NSAIDs, thiazide diuretics, statins and sulpha drugs) are identified, then a trial of cessation should be undertaken if clinically appropriate. 1, 3, 26 First-line treatment is topical application of corticosteroids. 5, 23 For non-erosive disease on glabrous skin, a cream-based, mid-to low-potency, nonfluorinated corticosteroid has been suggested to minimize maceration in this dynamic environment. 13 Mucosal disease, particularly erosive, is best treated with an ointment. Clobetasol propionate 0.05% is reported as able to suppress signs and/or reduce symptoms for erosive VLP in more than 90% of patients, although scarring is irreversible. 25 Available studies, albeit limited by the lack of large cohorts, agree that disease remission and maintenance is reliable with the use of clobetasol propionate 0.025-0.05% or fluocinolone acetonide 0.05-0.1% in all types of VLP. 2, 6, 14, 16, 23, 25 However, in the prescription of ultrapotent topical agents, it is important to note that the anatomical occlusion of genital skin, often increased by the use of incontinence garments, increases the potency and side effect profile of all corticosteroids. 17 As patients improve, tapering to the least-potent corticosteroid that is effective is advised. 5 Reports of candida superinfection, dermatophyte infections and herpes reactivation occurring secondarily to the use of steroids are numerous. 12 Treatment follow-up is essential, 23 although no evidence-based guidelines exist.
For vaginal disease, corticosteroid suppositories are an effective option with one study following 60 women treated twice daily initially then tapered to twice weekly after several months of encouraging disease remission. 28 Overall, 81% of women reported significant symptomatic relief and 76.8% of the women improved objectively on clinical examination. 25, 28 Vaginal stenosis, however, did not significantly improve.
In the context of severe pain or exacerbations, requirement for rapid symptom control or when severe scarring and adhesion formation is foreseen, the use of systemic corticosteroid alone or in combination with the use of a vaginal dilators has been effective. 2, 18 Dosage and duration of therapy with systemic steroids, such as prednisolone, vary in the literature but a common recommendation is 30-60 mg once daily for four to six weeks. 13, 18 The dilator is coated with corticosteroid or oestrogen vaginal cream and used on a tapering schedule at night but, unfortunately, symptoms recur immediately with the cessation of this regimen. 1, 18, 29 Furthermore, the potential side effects of the long-term use of corticosteroids necessitate the institution of alternative therapeutic agents.
In the light of VLP likely being a T-cell-mediated disorder, the use of topical calcineurin inhibitors has been explored with variable success. 30 Topical tacrolimus (0.1% or 0.03% ointment) is applied twice daily with symptomatic relief within 4 weeks. 31 Some studies have reported a sequential tapering to weekly treatment with sustained results but none of these regimes have been standardized or validated. 18 Along with a common side effect of burning sensation, calcineurin inhibitors carry an increased risk of malignancy even with minimal systemic absorption. 32, 33 Controlled clinical trials are warranted to explore its effectiveness and long-term risk profile. Pimecrolimus acts in a similar manner to tacrolimus but is thought to be more selective, and thus reportedly well tolerated, as it spares dendritic (Langerhans) cells. 30, 34 Notably, one randomized control trial saw it is effective in oral erosive LP. 35 A study of 11 patients with VLP treated with pimecrolimus, six (55%) of the women had a complete response and three (27%) were considered to have a partial response. 34 The data available on the use of systemic treatment are very limited. The best documented agent is low-dose methotrexate which is relatively safe and can be very effective therapy for patients with severe erosive VLP. 12, 18, 36 Doses between 2.5 and 12.5 mg alone or in combination with topical treatments demonstrate a clear response within 4-8 weeks. 5, 18, 37 In most reports, methotrexate had minor side effects and no adverse events or blood abnormalities. 18 The use of adalimumab, azathioprine, cyclosporine and mycophenolate mofetil has been the discussed in several studies but with numbers treated in studies ranged from only 3 to 10, their efficacy is as yet not confirmed with limited knowledge of their risk profile in this patient subset. 5, 14, 17, 18, 23, 25, [37] [38] [39] [40] A study of 40 women with VLP examined the use of photodynamic therapy and found that it was well tolerated and reduced the regular use of topical corticosteroids. 41 However, this small randomized, observer-blinded, controlled trial found no significant difference in the clinically efficacy of one session with vulvo-vaginal (hexyl 5-aminolevulinate-hydrocloride (HAL)-PDT compared with daily use of topical corticosteroids for 6 weeks based on standardized outcome measures devised by the authors. 41 Supportive measures are an important adjunct in management of these complex patients. Use of any irritating substances on the vulva (soaps, lotions or detergents) must Vulvovaginal lichen planusbe avoided with allergens and physical manipulation minimised. 13 Systemic antihistamines and topical plain emollients may help in controlling itching and rubbing. In postmenopausal patients, hormone replacement with topical or systemic oestrogen eliminates underlying atrophy caused by oestrogen deficiency. 42, 43 Vulvar SCC is a complication of VLP, although it is likely to occur less frequently than in patients with vulval lichen sclerosus. 44, 45 In one cohort (mean follow-up of 72 months), 2.4% of patients with LP had a history of or current genital malignant neoplasm. 32 This risk seems to be low and there is currently no data to suggest which patients are at increased risk of malignant transformation. 5, 29 A recent study reported that erosive VLP is associated with worse quality of life than those with lichen sclerosus with high rates of sexual distress. 46 We have not found any studies that quantified or qualitatively analysed the subjective impact that treatment has on patients with VLP. Therefore, the recent development and testing of a vulvar specific quality of life instrument known as the Vulvar Quality of Life Index (VQLI) is important. 47 The VQLI is intended as a selfadministered tool that can be completed in five minutes or less by a patient with any type of vulval disease. It consists of 15 questions with an aggregate score between 0 and 45 reflecting the level of patients' morbidity. 47 Its utility lies in its emphasis on impact of disease not only physically but on relationships and the psychosocial impact of vulval disease.
FUTURE RESEARCH
The Cochrane Group noted that lichen planus remains a condition plagued by a paucity of knowledge, consensus or a strong research base. 18 Indeed, whilst attempts have been made, no validated consensus exists on clinicopathological diagnosis and there is limited evidence for the efficacy of any one therapy for VLP apart from topical corticosteroids. Often, practitioners form conclusions from small studies in oral medicine rather than specific VLP studies or well-conducted and high powered randomised clinical trials. 5, 14, 23, 27 We are encouraged by the proposed hELP trial, the first randomised trial for second-line systemic treatment of erosive LP. 48 However, these gaps in knowledge must be rectified by large-scale, validated studies to enumerate diagnostic criterion and severity assessment tools. This must be accompanied by strong and well-conducted randomized studies comparing the most promising treatment agents. Additionally, a validated set of clinical outcome measures as well as specific standardized vulvar dermatology quality of life instrument to quantify the impact of disease and treatment to the patient experience.
Vulvo-vaginal lichen planus is suggested by a chronic, painful, erosive vulvo-vaginitis not explained by other diagnoses. It may be challenging to diagnose and is not always able to be confirmed histologically. The current best evidence for therapy for VLP is ultrapotent topical corticosteroid with the best-documented treatment being clobetasol 0.05% ointment. Beyond this, little is known and collaborative efforts to better inform clinicians are needed.
PRACTICE POINTS
• VLP is often a diagnosis of exclusion made collectively through clinical signs and symptoms, histopathology and low vaginal swabs.
• A trial of short-term treatment with topical corticosteroids is supported by current evidence.
• For more severe disease, systemic therapies may be warranted. The most studied and promising of these are oral prednisone and methotrexate.
• It is important to quantify disease burden at diagnosis and during management and the only specific and validated instrument to date is the VQLI.
